Business
Hinto Energy Acquires Novel Fibromyalgia Treatment IP
Hinto Energy Acquires Novel Fibromyalgia Treatment IP.
About this update from Hinto Energy, Inc.
[{"type":"text","content":"SHERIDAN, WY / ACCESSWIRE / March 14, 2023 / HINTO ENERGY, INC. (OTC:HENI) today announced a transaction, dated March 6, 2023 to acquire certain assets related to a development stage, novel treatment for fibromyalgia for consideration of 1,000,000 shares of the Company's preferred C shares from JF BioPharma Inc., in a related party transaction.Fibromyalgia syndrome (FMS) is a complex chronic multi-system disorder that affects 4% of the global population, mainly women aged 20-50 years. This intractable disease is characterized by diffuse musculoskeletal pain, fatigue, and depression. Without an effective therapy, FMS has a lifelong adverse impact on physical, social, and psychological well-being.In order to address this important unmet medical need, JF BIOPHARMA has invented a novel proprietary pharmaceutical treatment ("JF-100") that simultaneously targets three distinct and fundamental root causes of the disease.First, JF-100 is designed to directly modulate the endocannabinoid system in order to suppress the heightened sensitivity to pain that results from overactivation of a specific set of ion channels that transduce pain.Second, JF-100 can suppress oxidant stress that can damage mitochondria, the key part of the cell that is responsible for ensuring sufficient energy is available to maintain normal organ function and mitigate fatigue and depression.Lastly, JF-100 is designed to increase the efficiency of energy generation within the mitochondria, in order to maximize the level of cellular and organ activity for any given age and level of physical conditioning.By addressing the breadth of the disorder and targeting all three biological disease mechanisms in parallel, the Company has designed JF-100 as a first-line agent for treatment of FMS.Commenting on the utility of this combination approach, Dr. Andrew Salzman, the Company's Chief Scientist, remarked that "JF-100 can be viewed as a watershed advance in the treatment of FMS, because the drug is by design a multi-functional platform that addresses all three major mechanisms of disease. Customarily, treatments have been focused on a single aspect of FMS, and therefore have missed the opportunity to comprehensively address the full complexity of the disease process."To advance JF-100 towards regulatory approval, JF BIOPHARMA intends to initiate a Phase 2 ...